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Prospective Survey for the Etiology and Outcome of
Peptic Ulcer Bleeding: A Community Based Study 
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Daw-Shyong Perng,1 Chih-Wen Lin,1 Wen-Lun Wang,1 Jung-Der Wang,3,4,5 Jaw-Town Lin1,3*
Background/Purpose: Helicobacter pylori infection and drugs are the two major risk factors for peptic ulcer
bleeding. The role of these two factors may change with changes in the prevalence of H pylori and use of
NSAIDs. This study aimed to determine the cause, endoscopic features, and outcome of peptic ulcer bleeding
in a community hospital in southern Taiwan.
Methods: Patients who received esophagogastroduodenoscopy on arrival at the emergency department and
were found to have actively bleeding ulcers or ulcers with stigmata of recent hemorrhage were included. 
H pylori infection was documented by the rapid urease test, histology, and/or C-13 urease breath test.
Medication history, comorbidities, requirement for endoscopic therapy, blood transfusion, hospitalization
days, and rebleeding rates were analyzed.
Results: A total of 204 patients were enrolled with a mean age of 64.8 ± 15.2 years, with 58.3% of the subjects
being female. There were 62 patients (30.4%) with H pylori infection only, 40 patients (19.6%) with drug
use only, 67 patients (32.8%) with H pylori infection and drug use, and 37 patients (17.2%) without H pylori
or drug use. A total of 107 patients (52.5%) were found to have had drug exposure. Drug exposure had an
odds ratio (OR) of 2.34 [95% Confidence Interval (CI) = 1.30–4.20] for gastric ulcer bleeding and H pylori
had an OR of 2.64 (95% CI = 1.17–5.97) for combined gastric and duodenal ulcer bleeding. The mean
hospitalization period was 5.7 ± 4.0 days and the overall re-bleeding rate was 4.0%. The H pylori negative
and drug negative subjects needed more endoscopic therapy (p < 0.05).
Conclusion: Drug use, especially NSAIDs, aspirin, and clopidogrel has become an important cause of
peptic ulcer bleeding in southern Taiwan.
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Helicobacter pylori (H pylori) infection plays a sig-
nificant role in peptic ulcer disease, which is a
major cause of upper gastrointestinal (GI) bleed-
ing.1,2 Despite the introduction of H pylori eradi-
cation therapy, the rates of peptic ulcer-related
complications such as bleeding and perforation
have remained high.3 The cause of peptic ulcer
bleeding has been correlated to exposure to drugs,
especially non-steroidal anti-inflammatory drugs
(NSAID).4,5 Although the selective cyclooxygenase-
2 (COX-2) NSAIDs have less gastrointestinal tox-
icity, both selective and nonselective COX-2
NSAIDs have been shown to induce peptic ulcer-
related complications.6−9 Since NSAIDs are usually
prescribed for aged subjects with arthritis, NSAIDs-
related peptic ulcer disease becomes a vital issue
in the elderly.10
In the past, both H pylori infection and peptic
ulcer disease were prevalent in Taiwan.11 However,
recent studies indicate the prevalence of H pylori
infection and complications of peptic ulcer dis-
ease have been significantly reduced.12 Although
Taiwan has been a geriatric country since 1993,13
and the consumption of NSAIDs and low dose
aspirin have increased progressively in the recent
decade, the role of H pylori infection and expo-
sure to drugs such as NSAIDs and aspirin as the
causes of peptic ulcer bleeding in Taiwan is un-
determined. Additionally, the clinical outcome
of peptic ulcer bleeding due to different etiolo-
gies has not been investigated. More recently, the
H pylori negative and drug negative group has raised
the attention of researchers because of its charac-
teristic clinical course and outcome.14−16
The aim of this study is to determine the cause,
endoscopic features, and outcome of peptic ulcer
bleeding related to different etiologies in a com-
munity hospital in southern Taiwan.
Materials and Methods
Patients
This prospective study was conducted in consec-
utive patients who presented to the Emergency
Department (ED) of E-Da University Hospital
with tarry stool or hematemesis from July 1, 2007
to June 31, 2008. E-Da hospital a 1000 bed com-
munity hospital located in Kaohsiung County in
southern Taiwan, with a population of approxi-
mately 1,200,000. Most of the inhabitants are
elderly farmers and housewives. The hospital ED
receives approximately 200 outpatients daily.
Patients received emergent esophagogastro-
duodenoscopy (EGD) within 24 hours after arrival
at the ED. Patients with actively bleeding ulcers,
or ulcers with stigmata of recent hemorrhage on
EGD evaluation were enrolled. The exclusion cri-
teria were (1) bleeding from esophageal or gastric
varices; (2) Mallory-Weiss tear; (3) upper gastroin-
testinal malignancy; (4) chronic diseases with
bleeding tendency; and (5) age < 18 years.
The baseline demographic characteristics were
collected by structured interview and included age,
gender, clinical history, alcohol use, smoking, and
medication history. The drugs related to peptic
ulcer bleeding surveyed included non-selective
NSAIDs, selective COX-2 NSAIDs, warfarin, as-
pirin, clopidogrel, and other drugs with potential
risks of peptic ulcer bleeding. The patients who
received drug treatment within the recent 3 months
before peptic ulcer bleeding were defined as pos-
itive exposure. The amount of blood transfused,
rebleeding events, and days of hospitalization were
also recorded. This study was approved by the
Institutional Review Board of E-Da Hospital and
I-Shou University (IRB number: E-MRP-096-0019).
Endoscopic evaluation and H pylori
determination
EGD was performed by experienced endoscopists
using the Olympus Q260 endoscope (Tokyo,
Japan). If actively bleeding ulcers or ulcers with
stigmata of recent hemorrhage were noted by EGD,
therapeutic endoscopy was considered. After he-
mostasis, endoscopic biopsy from the non-ulcer
areas of the antrum was performed for the biopsy
urease test and histological examination for evi-
dence of H pylori infection. The biopsied speci-
mens were fixed in formalin, mounted, cut, and
then stained with hematoxylin and eosin for his-
tological examination. Giemsa stain was used to
C.Y. Chang, et al
224 J Formos Med Assoc | 2011 • Vol 110 • No 4
Etiology of peptic ulcer bleeding
J Formos Med Assoc | 2011 • Vol 110 • No 4 225
identify H pylori. If discordant results were noted,
the C-13 urease breath test (Helico-BT “K.M.”) was
further used to evaluate the status of H pylori in-
fection. H pylori infection was considered present
if two or all of the three tests (biopsy urease test,
histological examination, C-13 urease breath test)
were positive. The absence of H pylori infection
was defined as two of the three tests having neg-
ative results.
Statistical analysis
All subjects could be classified into four groups
according to drug exposure and H pylori status.
These groups were: H pylori infection only, drug
exposure only, combined H pylori infection and
drug exposure, neither H pylori infection or drug
exposure. The general linear model was applied to
compare the differences among the four groups.
A multiple linear regression model was utilized to
analyze the relationship between clinical outcome
and associated factors. A logistic regression model
was used to test the odds ratio (OR) of various risk
factors to different types of peptic ulcer. Statisti-
cal analyses were conducted by using SAS, version
9.1 (SAS Institute, Cary, NC, USA). A p value <0.05
was considered statistically significant.
Results
Demographic characteristics
A total of 414 patients with suspected upper GI
bleeding received EGD evaluation at the ED of the
E-Da University Hospital from July 1, 2007 to June
31, 2008. Of these patients, 204 subjects met the
inclusion criteria and were enrolled in the analysis.
The mean patient age was 64.8 ± 15.2 years and
58.3% of the subjects were females. There were
62 patients (30.4%) with H pylori infection only,
40 patients (19.6%) with drug use only, 67 pa-
tients (32.8%) with H pylori infection and drug
use, and 35 patients (17.2%) without H pylori in-
fection or drug use (Table 1). A total of 107 patients
(52.5%) were found to have had drug exposure
Table 1. Clinical and demographic characteristics of 204 patients with peptic ulcer bleedinga
Group 1 Group 2 Group 3 Group 4
H pylori + H pylori – H pylori + H pylori –Characteristics
Drug – Drug +b Drug + Drug –
p
(n = 62) (n = 40) (n = 67) (n = 35)
Age (yr) 65.4 ± 13.8 68.4 ± 15.7 63.2 ± 14.5 62.3 ± 17.7 0.26
Male gender 32 (51.6) 15 (37.5) 20 (29.9) 18 (51.4) 0.04* (group 1 vs. 3; 
group 4 vs. 3)
Smoking 23 (37.1) 10 (25) 33 (49.3) 15 (42.9) 0.09
Drinking 19 (30.6) 8 (20.0) 16 (23.9) 8 (22.9) 0.64
Comorbiditiesc 16 (25.8) 15 (37.5) 30 (44.8) 17 (48.6) 0.13
Hemoglobin (gm/dL) 9.9 ± 2.9 9.9 ± 2.6 10.1 ± 2.9 9.6 ± 3.1 0.84
Endoscopic findings
GU 20 (32.3) 23 (57.5) 38 (56.7) 15 (42.9) 0.02* (group 1 vs. 2; 
group 1 vs. 3)
DU 19 (30.6) 11 (27.5) 19 (28.4) 17 (48.6) 0.16
GU + DU 23 (37.1) 6 (15) 10 (14.9) 3 (8.5) < 0.01* (group 1 vs. 2; 
group 1 vs. 3; 
group 1 vs. 4)
aData are presented as n (%) or mean ± standard deviation; bdrugs including non-steroidal anti-inflammatory drugs (NSAIDs), aspirin,
clopidogrel, warfarin, and other medications which were not identified; cthe comorbidities were defined as chronic liver disease,
chronic renal disease, hypertension, diabetes mellitus, cardiovascular disease, cerebral vascular disease, malignant disease, chronic lung
disease, etc. GU = gastric ulcer; DU = duodenal ulcer. *p < 0.05.
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(Table 1). A summary of the drugs used and the
exposure time from use to gastrointestinal bleed-
ing is presented in Table 2. Non-selective COX-2
inhibitors tended to have a significantly shorter
latent period (mean exposure time, 3.7 ± 7.1 days)
compared with celecoxib (mean exposure time,
16.3±10.7 days) and others, including aspirin, clo-
pidogrel and combined therapy (mean exposure
time, 110.6 ± 97.6 days).
Endoscopy findings
After endoscopic examination, 96 patients (47.1%)
were found to have a gastric ulcer (GU), 66 pa-
tients (32.3%) a duodenal ulcer (DU), and 42
patients (20.6%) had combined GU and DU. 
H pylori infection was documented in 129 (63.2%)
subjects. Patients with H pylori infection were more
likely to have combined GU and DU (p < 0.05;
Table 1). However, GU only was more frequently
noted in patients with drug exposure (p < 0.05;
Table 1). Endoscopic therapy was administered to
50 patients (24.5%). Patients with neither H pylori
infection or drug exposure had a higher rate of re-
ceiving endoscopic therapy (40%) than patients
with both drug exposure and H pylori infection
(16.4%; p = 0.04; Table 3).
Outcome analysis
A total of 87 patients (42.6%) received a blood
transfusion due to acute upper GI bleeding with
a mean transfusion volume of packed red blood
cells (RBCs) of 1.1 ± 1.5 U (Table 3). There was
no significant difference in the amount of blood
transfused in the four groups (Table 3). The mean
duration of hospitalization was 5.7 ± 4.0 days, and
the overall rebleeding rate was 4.0%. One 77-year-
old male patient who was receiving warfarin ther-
apy for prevention of vascular thrombosis died of
bleeding with complications. After adjusting all
confounding factors, including age, gender, comor-
bidities, smoking, alcohol use, drug usage, H pylori
Table 3. Clinical outcomes of 204 patients with peptic ulcer bleedinga
Group 1 Group 2 Group 3 Group 4
H pylori + H pylori – H pylori + H pylori −Characteristics
Drug – Drug +b Drug + Drug –
p
(n = 62) (n = 40) (n = 67) (n = 35)
Received endoscopic therapy 13 (21.0) 12 (30.0) 11 (16.4) 14 (40) 0.04*
(group 3 vs. 4)
Rebleeding 0 (0) 2 (5.0) 3 (4.5) 3 (8.6) 0.35
Received blood transfusion 28 (45.2) 18 (45) 30 (44.8) 11 (31.4) 0.54
Blood transfusion (units) 1.2 ± 1.7 1.3 ± 1.6 1.1 ± 1.5 0.7 ± 1.2 0.35
Hospitalization (d) 5.0 ± 2.8 6.1 ± 5.2 5.4 ± 3.2 6.9 ± 5.2 0.14
aData are presented as n (%) or mean ± standard deviation; bdrugs including non-steroidal anti-inflammatory drugs (NSAIDs), aspirin,
clopidogrel, warfarin, and other medications which were not identified. GU = gastric ulcer; DU = duodenal ulcer. *p < 0.05.
Table 2. Summary of drugs used and the exposure
time to gastrointestinal bleeding
Exposure time (d)
Drug
Mean ± SD Median
Celecoxib (n = 3) 16.3 ± 10.7 14
Ketorolac (n = 13) 2.2 ± 3.6 1
Diclofenac (n = 2) 3.5 ± 0.7 4
Ibuprofen (n = 2) 1.5 ± 0.7 2
Indomethacin (n = 1) 12 12
Warfarin (n = 1) 10 10
Aspirin (n = 4) 187.5 ± 139.4 90
Clopidogrel (n = 5) 84.6 ± 61.9 90
Celecoxib + Aspirin (n = 1) 5 5
Ketorolac + Aspirin (n = 2) 1 1
Celecoxib + Clopidogrel 28 28
(n = 1)
Aspirin + Clopidogrel 14 14
(n = 1)
Other drugs (n = 66)a NA NA
aOther medication including drugs for arthralgia (n = 44), upper
airway infection (n = 19) and gout (n = 3). NA = not assessable.
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infection, initial hemoglobin level, and require-
ment for therapeutic endoscopy with the multi-
ple linear regression model, only H pylori infection
and initial hemoglobin level were independent fac-
tors negatively associated with duration of hospital-
ization. Drug exposure had an OR of 2.34 (95%
CI = 1.30–4.20) for gastric ulcer bleeding, and 
H pylori had an OR of 2.64 (95% CI = 1.17–5.97)
for combined gastric and DU bleeding.
Discussion
H pylori infection and drug exposure are two major
causes of upper gastrointestinal bleeding.1,2,4,5
After the introduction of H pylori eradication
therapy to prevent ulcers and bleeding, the pri-
mary cause of peptic ulcer bleeding has become
drug exposure, especially NSAIDs, in Western
countries.17
H pylori infection was common in Taiwan, with
a high prevalence of 54.4%.11 However, after the
introduction of H pylori eradication, peptic ulcer
related events such as bleeding and perforation
have decreased dramatically.12 By contrast, Taiwan
has become a geriatric country, with 10.4% of pop-
ulation over 65 years of age in 2008.13 NSAIDs
commonly used for pain relief in the elderly have
become one of the major causes of peptic ulcer
bleeding.18 The mean age of patients with peptic
ulcer bleeding in this study was 64.8 years, reflect-
ing a vulnerable population with frequent NSAID
exposure. Thus, more NSAID related ulcer bleed-
ing would be anticipated in Taiwan, and the major
etiology of peptic ulcer bleeding might shift from
H pylori infection to NSAID usage in the future.
In this study, 52.5% of patients with peptic
ulcer bleeding had a history of drug exposure
(Table 1). This indicates that drug exposure, rather
than H pylori infection, has become an important
cause of peptic ulcer bleeding in Taiwan. The
changing trend is likely related to an older popu-
lation with more frequent drug exposure, an over-
all improvement of the socioeconomic status, and
wide use of eradication therapy resulting in re-
duction of H pylori infection in Taiwan.12
Although drugs for relieving pain due to os-
teoarthritis or rheumatic arthritis are considered
to be the leading causes of peptic ulcer bleeding
in this study, direct evidence is still lacking be-
cause two-thirds of the patients with peptic ulcer
bleeding and history of drug exposure could not
accurately identify the names and compositions of
the drugs they used. In Taiwan, people may take
over-the-counter analgesics, antipyretics, NSAIDs,
and Chinese herbs for relieving symptoms of
arthralgia, myofacial pain, upper respiratory tract
infection, and gout, instead of using prescrip-
tions from physicians. Thus, it is very difficult to
determine a complete history of drug exposure.
Therefore, more education regarding drug safety
should be provided from the physicians and gov-
ernment in this aged population to prevent re-
current bleeding.
In our study, we found 25 definite users of
NSAIDs, including ketorolac, diclofenac, ibupro-
fen, indomethacin and celecoxib, and 44 users of
drugs for arthralgia that were likely to be NSAIDs;
thus, 61.7% (69 of 107) of patients may have drug-
induced ulcer bleeding related to NSAIDs. Our
study confirmed that even selective COX-2 in-
hibitors such as celecoxib can cause ulcer bleed-
ing.6−9 However, non-selective COX-2 inhibitors
tend to have a shorter latent period to bleeding in
contrast to celecoxib. This result is consistent with
previous studies.19,20 Whether this phenomenon
is related to genetic variation, such as polymor-
phism of the CPY2C9 gene,21 requires further 
investigation.
Aspirin, clopidogrel, and warfarin can also in-
duce ulcer bleeding. Aspirin used by patients in
this study was for the prevention of coronary ar-
tery disease, therefore a low dose (100 mg) was
used, with a median exposure time of 90 days. This
result is consistent with a previous study by Lanas
et al.6 Clopidogrel is increasingly used in patients
with coronary artery diseases with or without stent
therapy. The side effect of antiplatelet reactivity
may be peptic ulcer bleeding.22 In this study, the
ulcer bleeding in seven patients was related to
clopidogrel, and the exposure time was long (me-
dian exposure time, 90 days). Drugs used in the
C.Y. Chang, et al
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treatment of upper airway infection and gout in
this study were likely to be antipyretics, antibi-
otics, colchicine, and allopurinol, however, this
requires further confirmation.
The H pylori negative and drug negative group
accounted for 17.2% of the patients in this study.
This group required a greater number of thera-
peutic endoscopies than the other groups. The
duration of hospitalization for this group of pa-
tients also tended to be longer and rebleeding rate
tended to be higher (Table 3). The reason for the
relatively poor outcome of this group might be a
higher number of comorbidities in these patients
(Table 1). These results are consistent with previ-
ous studies.16 Reconfirmation of the results of 
H pylori testing, clarification of medical history,
exclusion of neoplasia or hypersecretion status,
and treatment for comorbidities should be consid-
ered a high priority in H pylori negative and drug
negative peptic ulcer disease.23 Further prospec-
tive studies are needed to clarify the underlining
etiology, clinical characteristics, and management
in this specific subgroup.
After adjusting all confounding factors using
the multiple linear regression model, only H pylori
infection and initial hemoglobin level were in-
dependent factors, and they were negatively as-
sociated to hospitalization days. In other words,
subjects with H pylori infection and high initial
hemoglobin level had a more favorable outcome.
This result is consistent with previous findings.24
Different etiologies of bleeding ulcers may re-
sult in a different profile of bleeding location. In
this study, drug exposure was frequently associ-
ated with gastric ulcer bleeding with an OR of
2.34, and the OR of H pylori infection for com-
bined gastric and duodenal ulcer bleeding was
2.64. These results confirmed similar findings from
other studies.25 They may provide information to
endoscopists to assist in differentiating potential
etiologies of peptic ulcer bleeding in individual
patients.
In conclusion, in addition to H pylori infection,
drug exposure, especially with NSAIDs, aspirin,
and clopidogrel have become an important, emerg-
ing cause of peptic ulcer bleeding in Taiwan. A new
and comprehensive preventive and therapeutic
strategy for peptic ulcer bleeding is mandatory in
the post-H pylori era.
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